The guideline group was selected to be representative of UK‐based medical experts. Recommendations are based on review of the literature using MEDLINE and PUBMED up to December 2013 under the heading: ‘tumour lysis syndrome’. The writing group produced the draft guideline. Review of the manuscript was performed by the British Committee for Standards in Haematology, BCSH Haemato‐oncology Task Force, BCSH Executive Committee and by the haemato‐oncology sounding board of the British Society for Haematology (BSH). This comprises over 50 members of the BSH who have reviewed the guidance and commented on its content and applicability in the UK setting. It has also been reviewed by representatives from Leukaemia and Lymphoma Research but they do not necessarily approve or endorse the contents. The ‘GRADE’ system was used to quote levels and grades of evidence (www.bcshguidelines.com). The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with tumour lysis syndrome (TLS). The guidance may not be appropriate to every patient and in all cases individual patient circumstances may dictate an alternative approach.
Jones, G. L., Will, A. , Jackson, G. H., Webb, N. J., Rule, S., the British Committee for Standards in Haematology, British Journal of Haematology 169: 661-671 First published: 15 April 2015
